Skip to main content
TipRanks
Go Ultimate75% OFF

Strata Critical Medical (SRTA) AI Stock Analysis

1,019 Followers
SRTA

Strata Critical Medical

(NASDAQ:SRTA)

Select Model
Rating:60Neutral
Price Target:$6.50▲(31.05% Upside)
Action:reiterated
Date:11/05/26

SRTA’s score is driven primarily by improving operations and upbeat, reaffirmed guidance from the earnings call, plus a very strong low-debt balance sheet. Offsetting this, current TTM profitability is still negative with only marginal free cash flow, technical momentum is mixed (negative MACD), and valuation is hampered by losses (negative P/E) with no dividend support.

Positive Factors
Strong revenue and gross profit growthRobust revenue and gross profit growth indicate expanding demand and successful contribution from clinical acquisitions. The improvement also increases operating leverage and provides a stronger base for future margin expansion, supporting durable earnings growth over the next several quarters.
Negative Factors
TTM profitability remains negativePersistent operating and net losses show that the business has not yet converted revenue growth into durable GAAP earnings. Negative profitability limits internally funded expansion, weakens return generation, and leaves results more dependent on successful margin improvement and acquisition execution.

Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%SRTA+18.10%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$468.04M
Dividend Yield
―
Average Volume (3M)
982.38K
Price to Earnings (P/E)
-17.1
Beta (1Y)
1.89
Revenue Growth
22.73%
EPS Growth
3.40%
Country
US
Employees
327
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Strata Critical Medical Business Overview & Revenue Model

Company Description

Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of hum...

Strata Critical Medical Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:15.89%|Next Earnings Date:Mar 16, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Highlights included substantial revenue, EBITDA, margin and free cash flow growth; continued clinical market-share gains; early achievement of the logistics margin target; strong liquidity; acquisition capacity; and a new share repurchase authorization. The company did face seasonal transplant declines, shorter logistics distances, lower logistics revenue and year-over-year logistics gross margin, a sequential decline in clinical gross margin, elevated stock-based compensation and a GAAP loss caused by noncash items. However, management reiterated 2026 guidance and its medium-term growth targets, and the positive operating and strategic developments significantly outweighed the stated challenges.

Positive Updates

Strong Q3 Revenue and Gross Profit Growth
Total revenue increased 50.3% year-over-year to $74.1 million from $49.3 million, driven by clinical acquisitions and growth, partially offset by logistics. Total gross profit increased 57.9% to $16.8 million from $10.7 million.

Negative Updates

Seasonal Industry Transplant Decline
The transplant system experienced above-average seasonality in Q3, with deceased donors and heart, liver and lung transplants falling approximately 7% quarter-over-quarter.

Company Guidance

Strata reiterated 2026 guidance for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million and free cash flow before aircraft and engine acquisitions of $15 million to $22 million; at the midpoint, this implies a low single-digit sequential increase in revenue in the fourth quarter, with Q4 growth driven primarily by clinical, logistics expected to be about flat quarter-over-quarter and gross margin expected to remain about flat sequentially. The company anticipates an increase in clinical gross margins moving into 2027 and remains confident in its medium-term financial targets for high teens organic adjusted EBITDA growth and 30% plus adjusted EBITDA growth, including acquisitions; stock-based compensation expense is expected to decline sequentially approximately 20% to 30% moving into Q4, with the lower run rate expected to persist since 2027, alongside a continued reduction in SG&A as a percentage of revenue.

Strata Critical Medical Financial Statement Overview

Summary

Financials are mixed: revenue is growing (TTM +9.7%) and operating cash flow turned positive ($10.4M), supported by a very low-leverage balance sheet (debt-to-equity ~0.01). However, profitability remains weak (TTM operating and net income still negative; net margin ~-8.8%) and free cash flow is only slightly positive ($0.3M) with uneven conversion, limiting the score despite the strong balance sheet.

Income Statement

34Negative

Balance Sheet

78Positive

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Sep 2021
Income Statement
Total Revenue280.76M197.14M248.69M225.18M146.12M50.53M
Gross Profit57.82M41.13M58.92M42.12M22.27M10.52M
EBITDA-9.02M-5.71M-21.60M-50.43M-22.31M-43.10M
Net Income-24.81M41.35M-27.31M-56.08M-27.26M-40.05M
Balance Sheet
Total Assets328.88M325.47M256.68M294.94M325.02M335.88M
Cash, Cash Equivalents and Short-Term Investments41.64M61.23M127.14M166.14M192.08M281.97M
Total Debt3.62M3.31M9.32M24.52M18.33M716.00K
Total Liabilities52.51M46.40M34.74M60.64M50.54M44.51M
Stockholders Equity276.38M279.07M221.94M234.30M274.49M291.37M
Cash Flow
Free Cash Flow320.00K-59.92M-35.51M-34.46M-37.86M-15.91M
Operating Cash Flow10.39M-48.91M-2.52M-32.35M-37.13M-15.62M
Investing Cash Flow12.57M69.75M-1.02M17.09M79.34M-321.34M
Financing Cash Flow-10.58M-8.91M-5.76M-76.00K-1.08M332.26M

Strata Critical Medical Technical Analysis

Technical Analysis SentimentNeutral
Last Price4.96

Price Trends

50DMA5.02Positive
100DMA5.26Negative
200DMA5.10Positive

Market Momentum

MACD0.20Negative
RSI51.37Neutral
STOCH47.08Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Neutral. The current price of 4.96 is below the 20-day moving average (MA) of 5.12, below the 50-day MA of 5.02, and below the 200-day MA of 5.10, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 51.37 is Neutral, neither overbought nor oversold. The STOCH value of 47.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SRTA.

Strata Critical Medical Risk Analysis

Strata Critical Medical disclosed 57 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Due to the effects of discontinued operations for the Passenger business, our historical financial results may not be comparable to current or future results.Q4, 2025
2.Restrictive covenants in our Credit Agreement may restrict our ability to pursue our business strategies and we may incur substantial additional indebtedness in the future.Q4, 2025
3.Any inability to realize the anticipated benefits of the sale of the Passenger business or acquisition of Keystone could negatively impact our stock price and our business and financial results.Q4, 2025

Strata Critical Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SRTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UHSUHS76Outperform$10.73B7.7219.54%0.43%8.00%13.14%
HCAHCA64Neutral$99.51B15.74-100.45%0.64%5.82%16.59%
ARDTARDT63Neutral$2.03B13.859.48%―2.03%-28.50%
SRTASRTA60Neutral$468.04M-17.06-8.86%―22.73%3.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AUNAAUNA50Neutral$309.37M61.980.90%―16.82%-93.67%
CYHCYH44Neutral$284.87M6.89-2.51%―-7.84%-88.93%

* Healthcare Sector Average

Performance Comparison

0%50%100%SRTACYHHCAUHSAUNAARDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SRTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SRTAStrata Critical Medical, Inc.4.960.9323.08%
CYHCommunity Health Systems1.86-1.08-36.73%
HCAHca Healthcare476.353.310.70%
UHSUniversal Health Services186.07-38.33-17.08%
AUNAAuna S.A. Class A4.18-0.65-13.46%
ARDTArdent Health Partners, Inc.14.405.7666.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026